Dianthus Therapeutics, Inc. /DE/ (DNTH) FY2025 10-K Annual Report
Dianthus Therapeutics, Inc. /DE/ (DNTH) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Mar 9, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Dianthus Therapeutics, Inc. /DE/ FY2025 10-K Analysis
Business Overview
- • Core business: Development of claseprubart and DNTH212 biopharmaceutical candidates reliant on outsourced manufacturing and clinical trial services
- • New emphasis: Impact of the BIOSECURE Act (Dec 2025) restricting collaborations with certain Chinese biotech firms, including sole manufacturer WuXi Biologics
- • Strategic risk shift: Heightened regulatory and geopolitical exposure due to reliance on Chinese contract manufacturers amid increasing U.S.-China trade tensions
- • Notable metric: Sole supplier WuXi Biologics in China for claseprubart, with significant supply chain and regulatory risks highlighted in detail
- • Unusual fact: First-year reporting impact of U.S. BIOSECURE Act posing potential federal contract and funding prohibitions involving designated Chinese "biotechnology companies of concern"
Management Discussion & Analysis
- • No revenue reported, no year-over-year change disclosed
- • Net loss reported; specific profitability or margin figures not provided
- • No segment performance data detailed
- • Cash flow usage: capital expenditures and operating expenses incurred, no buybacks or dividends mentioned
- • Forward-looking: general caution on risks and uncertainties, no specific guidance or outlook disclosed
Risk Factors
- • Regulatory risk: Dependence on FDA approval for claseprubart and DNTH212 with uncertain timing and outcomes for clinical trial phases and marketing approvals
- • Geopolitical risk: License and development agreements with Tenacia Biotechnology for Greater China involving clinical trial cost sharing and milestone payments up to $15 million
- • Operational risk: Reliance on third-party CROs and CDMOs for clinical trials and manufacturing with no owned laboratory or manufacturing facilities
- • Competitive risk: Significant R&D spending $145.6M in 2025 to advance claseprubart and DNTH212 amid competition from other biopharma firms in autoimmune neurology space
- • Financial risk: Net loss $162.3M in 2025 with cash runway into 2028; future capital needs may dilute shareholders via ATM $200M equity offering capacity
Dianthus Therapeutics, Inc. /DE/ FY2025 Key Financial MetricsXBRL
Revenue
$2M
▼ -67.3% YoY
Net Income
-$162M
▼ -91.1% YoY
Operating Margin
-8739.3%
▼ -710560bp YoY
Net Margin
-7973.3%
▼ -661056bp YoY
ROE
-32.9%
▼ -880bp YoY
Total Assets
$531M
▲ +42.0% YoY
EPS (Diluted)
$-4.20
▼ -64.7% YoY
Operating Cash Flow
-$129M
▼ -65.1% YoY
Source: XBRL data from Dianthus Therapeutics, Inc. /DE/ FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Dianthus Therapeutics, Inc. /DE/
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.